Form Type: 4

SEC EDGAR Link
Accession Number:0001209191-23-017996
Date:2023-03-08
Issuer: TARSUS PHARMACEUTICALS, INC. (TARS)
Original Submission Date:

Reporting Person:

AZAMIAN BOBAK R.
C/O TARSUS PHARMACEUTICALS, INC.
15440 LAGUNA CANYON ROAD, SUITE 160 IRVINE, CA 92618

Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
Title of SecurityTransaction Date2a. Deemed Execution Date Transaction CodeSharesAcquired or DisposedPrice per share 5. Amount of Securities Beneficially Owned Following Reported Transaction 6. Ownership Form Direct or IndirectNature of Indirect Ownership
Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, convertible securities
Title of Derivative Security Conversion or Exercise Price of Derivative Security Transaction Date Deemed Execution Date Transaction Code Number of Derivative Securities Acquired (A) or Disposed of (D) Date ExercisableExpiration Date Title and Amount of Securities Underlying Derivative Security Price of Derivative Security Number of derivative Securities Beneficially Owned Following Reported Transaction(s) Ownership Form: Direct (D) or Indirect (I) Nature of Indirect Beneficial Ownership
STOCK OPTION (RIGHT TO BUY) 15.0 2023-03-08 deemed execution date A 100,242 (a) 2033-03-08 common stock 100,242 $15.00 100,242 direct
RESTRICTED STOCK UNITS 0.0 2023-03-08 deemed execution date A 67,900 (a) common stock 67,900 $0.00 67,900 direct
Footnotes
IDfootnote
f1 25% of the option shares shall vest on march 8, 2024, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years subject to the reporting person's continuous service.
f2 each restricted stock unit ("rsu") represents a contingent right to receive one share of the company's common stock.
f3 25% of the rsus will vest on march 15th of each of 2024, 2025, 2026, and 2027, subject to the reporting person's continuous service.
WhaleWisdom Logo

Elevate your investments